Đang chuẩn bị liên kết để tải về tài liệu:
Identification of SPRYD4 as a tumour suppressor predicts prognosis and correlates with immune infiltration in cholangiocarcinoma
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Cholangiocarcinoma (CCA) is an aggressive solid tumour with a 5-year survival rate ranging from 7% to 20%. It is, therefore, urgent to identify novel biomarkers and therapeutic targets to improve the outcomes of patients with CCA. |